Avalo Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
20.5%projected annual EPS growth
Analyst Coverage
13analysts covering
FY EPS (est.)
-$2.55next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Phase 2 LOTUS Trial Primary Endpoint (HiSCR75 at Week 16) Event-driven42.5Target: Statistically significant improvement over placebo (achieved 42.2% for 150mg and 42.9% for 300mg vs 25.6% placebo)
Cash Runway (Years) Quarterly2KTarget: Fund operations into 2028
R&D Expense (USD Millions) Quarterly50.1Target: Efficient allocation to registrational Phase 3 program
Watch Items
- Initiation of Registrational Phase 3 Program for Abdakibart (AVTX-009) in Hidradenitis SuppurativaTrigger: FDA alignment on Phase 3 trial design and protocolAction: Review clinical trial design, patient enrollment targets, and projected timeline to market
- Development Progress of AVTX-010 (Long-Acting Next-Generation Anti-IL-1̲ Antibody)Trigger: IND filing or Phase 1 trial initiationAction: Evaluate preclinical safety data and pharmacokinetic profile for extended dosing intervals
Research as of 20 Jun 2026